Trial Profile
A Phase ll trial to measure the response rate (Rate of recurrence following treatment) ,toxicity and safety of weekly intravesical gemcitabine in patients with transitional cell carcinoma of the bladder.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jun 2016
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 08 Jun 2016 Status changed from recruiting to completed.
- 30 Aug 2011 New trial record